PSC
SYRE icon

Patient Square Capital’s Spyre Therapeutics SYRE Stock Holding History

Patient Square Capital’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,000
Closed -$50.4K – 34
2026
Q1 		$50.4K Sell
1,000
-149,000
-99% -$5.62M 0.01% 29
2025
Q4 		$4.91M Buy
+150,000
New +$3.92M 1.05% 22

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Patient Square Capital's SYRE Position: Q2 2026 in Review

Patient Square Capital sold out of Spyre Therapeutics (SYRE) in Q2 2026, closing a stake of 1,000 shares — an estimated $50.4K sold.

Patient Square Capital first reported a position in SYRE in Q4 2025 and held it in 2 quarters. The position peaked at $4.91M in Q4 2025. 265 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • Patient Square Capital reported no remaining Spyre Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Patient Square Capital sold 1,000 Spyre Therapeutics shares in Q2 2026, an estimated $50.4K.
  • Patient Square Capital first reported a position in Spyre Therapeutics in Q4 2025 and held it in 2 quarters.
  • Patient Square Capital's Spyre Therapeutics position peaked at $4.91M in Q4 2025.
  • 265 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on Patient Square Capital's 13F filing for Q2 2026, filed 12 Aug 2026.